Author

Venkateshwar Mutyam

University of Alabama at Birmingham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Anita GoleciD· 1 shared Aurélie HattoniD· 1 shared Batsheva KeremiD· 1 shared Chen LeibsoniD· 1 shared Efrat Ozeri-GalaiiD· 1 shared Eitan KeremiD· 1 shared Eric J. SorscheriD· 1 shared Isabelle Sermet‐GaudelusiD· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetics

Anita GolecORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation

Yifat S. Oren, Michal Irony‐Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Li Yao, Jeong Shin Hong, Efrat Ozeri-Galai, Aurélie Hatton, Chen Leibson, Liran Carmel, Joel M. Reiter, Eric J. Sorscher, Steve Donald Wilton, Eitan Kerem, , Batsheva Kerem

This study develops an antisense oligonucleotide (ASO) therapy for CF patients with the 3849+10kb C-to-T splicing mutation, showing restoration of CFTR function in patient-derived cells.

Journal of Cystic Fibrosis · Jul 2, 2021Peer-reviewedGenetics